AU2020317099A1 - Selective estrogen receptor degrader - Google Patents

Selective estrogen receptor degrader Download PDF

Info

Publication number
AU2020317099A1
AU2020317099A1 AU2020317099A AU2020317099A AU2020317099A1 AU 2020317099 A1 AU2020317099 A1 AU 2020317099A1 AU 2020317099 A AU2020317099 A AU 2020317099A AU 2020317099 A AU2020317099 A AU 2020317099A AU 2020317099 A1 AU2020317099 A1 AU 2020317099A1
Authority
AU
Australia
Prior art keywords
compound
formula
cancer
less
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020317099A
Other languages
English (en)
Inventor
Jayraj Dilipbhai Aradhye
Trinadha Rao Chitturi
Ranjan Kumar Pal
Bhavesh Mohanbhai Panchal
Sandeep Pankajkumar PATHAK
Kaushik Dhanjibhai PRAJAPATI
Biswajit Samanta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of AU2020317099A1 publication Critical patent/AU2020317099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020317099A 2019-07-22 2020-07-22 Selective estrogen receptor degrader Abandoned AU2020317099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
AU2020317099A1 true AU2020317099A1 (en) 2022-02-24

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020317099A Abandoned AU2020317099A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Country Status (15)

Country Link
US (2) US11014915B2 (https=)
EP (1) EP4003525A1 (https=)
JP (1) JP2022541938A (https=)
KR (1) KR20220046586A (https=)
CN (1) CN114302879A (https=)
AU (1) AU2020317099A1 (https=)
BR (1) BR112022001285A2 (https=)
CA (1) CA3148592A1 (https=)
CL (1) CL2022000156A1 (https=)
IL (1) IL290036A (https=)
MX (1) MX2022001013A (https=)
PE (1) PE20221588A1 (https=)
PH (1) PH12022550182A1 (https=)
WO (1) WO2021014386A1 (https=)
ZA (1) ZA202201157B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) * 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
CN114127054B (zh) 2019-07-22 2024-04-09 勃林格殷格翰国际有限公司 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
CA3243621A1 (en) * 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
CA2915534A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
US20160175284A1 (en) * 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
WO2017072792A1 (en) * 2015-10-27 2017-05-04 Sun Pharma Advanced Research Company Limited Novel heterocyclic antiestrogens
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
CL2022000156A1 (es) 2022-11-18
WO2021014386A1 (en) 2021-01-28
PE20221588A1 (es) 2022-10-10
JP2022541938A (ja) 2022-09-28
PH12022550182A1 (en) 2022-11-14
EP4003525A1 (en) 2022-06-01
BR112022001285A2 (pt) 2022-03-22
KR20220046586A (ko) 2022-04-14
CA3148592A1 (en) 2021-01-28
US20210024504A1 (en) 2021-01-28
US11014915B2 (en) 2021-05-25
CN114302879A (zh) 2022-04-08
IL290036A (en) 2022-03-01
US20210261534A1 (en) 2021-08-26
MX2022001013A (es) 2022-02-22

Similar Documents

Publication Publication Date Title
US11014915B2 (en) Selective estrogen receptor degrader
US20240131013A1 (en) TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
US7696357B2 (en) Stable hydrate of a muscarinic receptor antagonist
CN1181077A (zh) 苯并吡喃类化合物及其使用方法
JP2023126540A5 (https=)
CA2695126A1 (en) Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
WO2023220404A1 (en) Treatment of non-alcoholic steatohepatitis
EP2911660A1 (en) Compositions and methods for treating estrogen-related medical disorders
Halama et al. Improved process for the preparation of montelukast: development of an efficient synthesis, identification of critical impurities and degradants
US7632963B2 (en) Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
US20110200687A1 (en) Bifeprunox mesylate maintenance dose compositions and methods for using the same
NZ205782A (en) 3-aminopropoxyphenyl derivatives and pharmaceutical compositions
EP2275099A1 (en) Treatment of faecal incontinence with 1r,2s-methoxamine
JPWO2004031125A1 (ja) スピロ化合物、それを含有する医薬組成物及び該化合物の中間体
EP1171133B1 (en) R-hydroxynefazodone
RU2855858C2 (ru) ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
EP4306115A1 (en) Pharmaceutical composition, and preparation method therefor and application thereof
WO2025255358A1 (en) Solid forms of posiphen d-tartrate and processes of preparation thereof
CN1141042A (zh) 旋光对映纯的(+)-利罗唑
JP2025523065A (ja) アゾポドフィロトキシン誘導体ｓｕ０５６のエナンチオマー
US20250197420A1 (en) Macrocyclic compounds, compositions, and methods of using thereof
HK1124337A (en) Nuclear receptor binding agents
HK1009440B (en) Benzopyran-containing compounds and method for their use

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period